New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers
Mira Dx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation therapy, surgery, and/or hormone therapy Radiation […]
Read MoreContact Us
CLIA certified and CAP Accredited Lab Address
Administrative Address
Information
- Privacy Policy
- Financial Conflict of Interest Policy
- Mira Dx CLIA certification # 07D2006340
- Mira Dx CAP accreditation # 8861922